Advertisement

Clinical Drug Investigation

, Volume 35, Issue 10, pp 653–657 | Cite as

Association of Meloxicam Use with the Risk of Acute Pancreatitis: A Case–Control Study

  • Shih-Wei Lai
  • Cheng-Li Lin
  • Kuan-Fu LiaoEmail author
Original Research Article

Abstract

Background and Objective

No sufficient research has focused on the relationship between meloxicam use and acute pancreatitis. This study aimed to explore this issue in Taiwan.

Methods

This case–control study was conducted using the database of the Taiwan National Health Insurance Program. In all, there were 6780 cases aged 20–84 years who were newly diagnosed with acute pancreatitis during the period 1998–2011, and 21,393 control subjects without acute pancreatitis. Cases and controls were matched for sex, age and comorbidities. Odds ratios (ORs) and 95 % confidence intervals (CIs) were measured to explore the associations between acute pancreatitis, meloxicam use and comorbidities, using a multivariable unconditional logistic regression model.

Results

After controlling for potential confounding factors, the adjusted OR for acute pancreatitis was 1.76 (95 % CI 1.30–2.40) for subjects with current use of meloxicam, in comparison with subjects who had never used meloxicam. The adjusted OR decreased to 1.29 (95 % CI 0.82–2.03) for subjects with late use of meloxicam, but without statistical significance.

Conclusions

Current use of meloxicam is associated with increased odds of acute pancreatitis. Clinicians should consider the potential risk of acute pancreatitis when prescribing meloxicam.

Keywords

Chronic Obstructive Pulmonary Disease Chronic Kidney Disease Acute Pancreatitis Meloxicam Biliary Stone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Specific Author Contributions

Shih-Wei Lai substantially contributed to the conception of the article. He planned and conducted this study, initiated the draft of the article and critically revised the article.

Cheng-Li Lin conducted the data analysis and critically revised the article.

Kuan-Fu Liao planned and conducted this study, participated in the data interpretation and critically revised the article.

Compliance with Ethical Standards

Funding

This study was supported in part by the Taiwan Ministry of Health and the Welfare Clinical Trial and Research Center of Excellence (Grant No. MOHW104-TDU-B-212-113002), China Medical University Hospital, Academia Sinica Taiwan Biobank, Stroke Biosignature Project (Grant No. BM104010092), NRPB Stroke Clinical Trial Consortium (Grant No. MOST 103-2325-B-039-006), Tseng-Lien Lin Foundation, Taichung, Taiwan, Taiwan Brain Disease Foundation, Taipei, Taiwan, and Katsuzo and Kiyo Aoshima Memorial Funds in Japan. These funding agencies did not influence the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflict of interest statement

The authors disclose no conflicts of interest.

References

  1. 1.
    Barner A. Review of clinical trials and benefit/risk ratio of meloxicam. Scand J Rheumatol Suppl. 1996;102:29–37.CrossRefPubMedGoogle Scholar
  2. 2.
    Fleischmann R, Iqbal I, Slobodin G. Meloxicam. Expert Opin Pharmacother. 2002;3(10):1501–12.CrossRefPubMedGoogle Scholar
  3. 3.
    eHealthMe: Personalized Health Information. Review: could meloxicam cause pancreatitis? http://www.ehealthme.com/ds/meloxicam/pancreatitis [cited 2014 December].
  4. 4.
    Sorensen HT, Jacobsen J, Norgaard M, Pedersen L, Johnsen SP, Baron JA. Newer cyclo-oxygenase-2 selective inhibitors, other non-steroidal anti-inflammatory drugs and the risk of acute pancreatitis. Aliment Pharmacol Ther. 2006;24(1):111–6.CrossRefPubMedGoogle Scholar
  5. 5.
    National Health Insurance Research Database. Background. http://nhird.nhri.org.tw/en/Background.html [cited 2014 December].
  6. 6.
    Lai SW, Muo CH, Liao KF, Sung FC, Chen PC. Risk of acute pancreatitis in type 2 diabetes and risk reduction on anti-diabetic drugs: a population-based cohort study in Taiwan. Am J Gastroenterol. 2011;106(9):1697–704.CrossRefPubMedGoogle Scholar
  7. 7.
    Liao KF, Lai SW, Li CI, Chen WC. Diabetes mellitus correlates with increased risk of pancreatic cancer: a population-based cohort study in Taiwan. J Gastroenterol Hepatol. 2012;27(4):709–13.CrossRefPubMedGoogle Scholar
  8. 8.
    Lai SW, Liao KF, Lin CL, Chen PC. Pyogenic liver abscess correlates with increased risk of acute pancreatitis: a population-based cohort study. J Epidemiol. 2015;25(3):246–53.PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Lai SW, Lai HC, Lin CL, Liao KF, Tseng CH. Chronic osteomyelitis correlates with increased risk of acute pancreatitis in a case–control study in Taiwan. Eur J Intern Med. 2015;26(6):429–32.CrossRefPubMedGoogle Scholar
  10. 10.
    Nitsche C, Maertin S, Scheiber J, Ritter CA, Lerch MM, Mayerle J. Drug-induced pancreatitis. Curr Gastroenterol Rep. 2012;14(2):131–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Bugdaci MS, Oztekin E, Kara E, Koker I, Tufan A. Prognostic value of increased B type natriuretic peptide in cases with acute pancreatitis. Eur J Intern Med. 2012;23(4):e97–100.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.College of MedicineChina Medical UniversityTaichung CityTaiwan
  2. 2.Department of Family MedicineChina Medical University HospitalTaichung CityTaiwan
  3. 3.Management Office for Health DataChina Medical University HospitalTaichung CityTaiwan
  4. 4.College of MedicineTzu Chi UniversityHualien CityTaiwan
  5. 5.Department of Internal MedicineTaichung Tzu Chi General HospitalTaichung CityTaiwan
  6. 6.Graduate Institute of Integrated MedicineChina Medical UniversityTaichung CityTaiwan

Personalised recommendations